These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 24909234)

  • 1. Biotransformation and bioactivation reactions of alicyclic amines in drug molecules.
    Bolleddula J; DeMent K; Driscoll JP; Worboys P; Brassil PJ; Bourdet DL
    Drug Metab Rev; 2014 Aug; 46(3):379-419. PubMed ID: 24909234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioactivation of drugs: risk and drug design.
    Walsh JS; Miwa GT
    Annu Rev Pharmacol Toxicol; 2011; 51():145-67. PubMed ID: 21210745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the diversity of oxidative bioactivation reactions on nitrogen-containing xenobiotics.
    Kalgutkar AS; Dalvie DK; O'Donnell JP; Taylor TJ; Sahakian DC
    Curr Drug Metab; 2002 Aug; 3(4):379-424. PubMed ID: 12093357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-cytochrome P450-mediated bioactivation and its toxicological relevance.
    Gan J; Ma S; Zhang D
    Drug Metab Rev; 2016 Nov; 48(4):473-501. PubMed ID: 27533622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes.
    Castagnoli N; Rimoldi JM; Bloomquist J; Castagnoli KP
    Chem Res Toxicol; 1997 Sep; 10(9):924-40. PubMed ID: 9305573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cyclic tertiary amine bioactivation to reactive iminium species: structure toxicity relationship.
    Mašič LP
    Curr Drug Metab; 2011 Jan; 12(1):35-50. PubMed ID: 21222587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory mechanisms in the activation of nitrogenous compounds by mammalian cytochrome P-450 isozymes.
    Hlavica P
    Drug Metab Rev; 1994; 26(1-2):325-48. PubMed ID: 8082573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbon-carbon bond cleavage and formation reactions in drug metabolism and the role of metabolic enzymes.
    Bolleddula J; Chowdhury SK
    Drug Metab Rev; 2015; 47(4):534-57. PubMed ID: 26390887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive listing of bioactivation pathways of organic functional groups.
    Kalgutkar AS; Gardner I; Obach RS; Shaffer CL; Callegari E; Henne KR; Mutlib AE; Dalvie DK; Lee JS; Nakai Y; O'Donnell JP; Boer J; Harriman SP
    Curr Drug Metab; 2005 Jun; 6(3):161-225. PubMed ID: 15975040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-oxidative transformation of free and N-substituted amine functions by cytochrome P450 as means of bioactivation and detoxication.
    Hlavica P
    Drug Metab Rev; 2002 Aug; 34(3):451-77. PubMed ID: 12214660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of the metabolic activation of alicyclic amines via aldehyde.
    Miura M; Hori W; Kasahara Y; Nakagawa I
    J Pharmacol Toxicol Methods; 2010; 61(1):44-51. PubMed ID: 19903534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.
    Tang W; Lu AY
    Drug Metab Rev; 2010 May; 42(2):225-49. PubMed ID: 19939207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting reactive drug metabolites for reducing the potential for drug toxicity.
    Grillo MP
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1281-302. PubMed ID: 26005795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemical toxicology of reactive intermediates formed by the glutathione-dependent bioactivation of halogen-containing compounds.
    Anders MW
    Chem Res Toxicol; 2008 Jan; 21(1):145-59. PubMed ID: 17696489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
    Guengerich FP
    AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.
    Kalgutkar AS; Driscoll J; Zhao SX; Walker GS; Shepard RM; Soglia JR; Atherton J; Yu L; Mutlib AE; Munchhof MJ; Reiter LA; Jones CS; Doty JL; Trevena KA; Shaffer CL; Ripp SL
    Chem Res Toxicol; 2007 Dec; 20(12):1954-65. PubMed ID: 17935300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro screening techniques for reactive metabolites for minimizing bioactivation potential in drug discovery.
    Prakash C; Sharma R; Gleave M; Nedderman A
    Curr Drug Metab; 2008 Nov; 9(9):952-64. PubMed ID: 18991592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimising the potential for metabolic activation in drug discovery.
    Kalgutkar AS; Soglia JR
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):91-142. PubMed ID: 16922655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytochrome p450 and chemical toxicology.
    Guengerich FP
    Chem Res Toxicol; 2008 Jan; 21(1):70-83. PubMed ID: 18052394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing metabolic activation as an integral component of drug design.
    Doss GA; Baillie TA
    Drug Metab Rev; 2006; 38(4):641-9. PubMed ID: 17145693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.